Literature DB >> 19234822

The effect of oral and IV ramosetron on postoperative nausea and vomiting in patients undergoing gynecological laparoscopy with total intravenous anesthesia.

Dongchul Lee1, Ji Young Kim, Jin Woo Shin, Chun Hoe Ku, Yeon Soo Park, Hyun Jeong Kwak.   

Abstract

PURPOSE: Ramosetron can be administered orally as well as intravenously. We investigated the effect of oral ramosetron on postoperative nausea and vomiting (PONV) in patients undergoing gynecological laparoscopy.
METHODS: One hundred and twenty women were allocated randomly to one of three groups (n = 40 in each) to receive saline (control), 0.1 mg oral ramosetron (PO), or 0.3 mg IV ramosetron (IV). Total intravenous anesthesia (TIVA) with propofol and remifentanil was used in all patients.
RESULTS: The incidence of complete response (no PONV, no rescue) in the control, IV, and PO groups was: 65%, 90%, and 87.5%, respectively, during the first 1 h; and 67.5%, 87.5%, and 80%, respectively, during 1 to 24 h.
CONCLUSION: The effect of oral ramosetron 0.1 mg was comparable to that of IV ramosetron 0.3 mg on the prevention of PONV in women undergoing gynecological laparoscopy with TIVA. Both the oral and IV forms were effective at preventing PONV during the first 1 h after surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19234822     DOI: 10.1007/s00540-008-0693-4

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  18 in total

1.  The cost-effective management of postoperative nausea and vomiting.

Authors:  M F Watcha
Journal:  Anesthesiology       Date:  2000-04       Impact factor: 7.892

2.  Randomized comparison of two anti-emetic strategies in high-risk patients undergoing day-case gynaecological surgery.

Authors:  H White; R J Black; M Jones; G C Mar Fan
Journal:  Br J Anaesth       Date:  2007-02-22       Impact factor: 9.166

3.  The antiemetic action of propofol.

Authors:  J S McCollum; K R Milligan; J W Dundee
Journal:  Anaesthesia       Date:  1988-03       Impact factor: 6.955

Review 4.  Propofol. An update on its clinical use.

Authors:  I Smith; P F White; M Nathanson; R Gouldson
Journal:  Anesthesiology       Date:  1994-10       Impact factor: 7.892

5.  Development of reliable and valid measures of nausea and vomiting.

Authors:  V A Rhodes; P M Watson; M H Johnson
Journal:  Cancer Nurs       Date:  1984-02       Impact factor: 2.592

6.  Comparison of ramosetron and granisetron for preventing postoperative nausea and vomiting after gynecologic surgery.

Authors:  Y Fujii; Y Saitoh; H Tanaka; H Toyooka
Journal:  Anesth Analg       Date:  1999-08       Impact factor: 5.108

7.  A randomized, double-blind, placebo-controlled trial of ramosetron for preventing nausea and vomiting during termination of pregnancy.

Authors:  Y Fujii; H Tanaka; Y Somekawa
Journal:  Int J Obstet Anesth       Date:  2004-01       Impact factor: 2.603

8.  Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery.

Authors:  M F Watcha; I Smith
Journal:  J Clin Anesth       Date:  1994 Sep-Oct       Impact factor: 9.452

9.  Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting.

Authors:  Y Fujii; H Tanaka; H Toyooka
Journal:  Can J Anaesth       Date:  1994-09       Impact factor: 5.063

10.  Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following major gynaecological surgery.

Authors:  T H Madej; K H Simpson
Journal:  Br J Anaesth       Date:  1986-08       Impact factor: 9.166

View more
  9 in total

1.  Does ramosetron reduce postoperative emesis and pain after TKA?

Authors:  In Jun Koh; Chong Bum Chang; Young-Tae Jeon; Jung-Hee Ryu; Tae Kyun Kim
Journal:  Clin Orthop Relat Res       Date:  2011-12-13       Impact factor: 4.176

Review 2.  Update on the management of postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

3.  A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period.

Authors:  Tae Soo Hahm; Jung Won Hwang; Won Ho Kim; Eun Jung Oh; Duk-Kyung Kim; Won Joon Choi; Yun Hong Kim; Jung Hee Ryu; Byung Hoon Yoo; Jun Heum Yon
Journal:  J Anesth       Date:  2014-07-19       Impact factor: 2.078

4.  Is it necessary to use prophylactics for preventing PONV?

Authors:  Jae Hang Shim
Journal:  Korean J Anesthesiol       Date:  2011-08-23

5.  The preventative effect of ramosetron on postoperative nausea and vomiting after total thyroidectomy.

Authors:  Dong Chul Lee; Hyun Jeong Kwak; Hong Soon Kim; Sung Ho Choi; Ji Yeon Lee
Journal:  Korean J Anesthesiol       Date:  2011-08-23

6.  Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis.

Authors:  Won Oak Kim; Bon Nyeo Koo; Yong Kook Kim; Hae Keum Kil
Journal:  Korean J Anesthesiol       Date:  2011-11-23

7.  Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.

Authors:  Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke
Journal:  Cochrane Database Syst Rev       Date:  2020-10-19

8.  Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study.

Authors:  Shoou-Chern Li; Youngmi Wang; Seong Jin Choi; Yeon Soo Jung; Kyoung-Hee Han; In Bai Chung; San-Hui Lee
Journal:  Obstet Gynecol Sci       Date:  2019-07-23

9.  The effectiveness of ramosetron and ondansetron for preventing postoperative nausea and vomiting after arthroscopic rotator cuff repair: a randomized controlled trial.

Authors:  Sang-Uk Lee; Hyo-Jin Lee; Yang-Soo Kim
Journal:  J Orthop Surg Res       Date:  2020-11-11       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.